A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in theMEA115588 or MEA115575 Trials
A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in theMEA115588 or MEA115575 Trials
This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study.
Inclusion Criteria:
Exclusion Criteria:
Gunma, 370-0615, Japan
Hokkaido, 070-8644, Japan
Donggu Gwangju, 501757, South Korea
Kangwon-do, 220-701, South Korea
Pozuelo de Alarcón/Madrid, 28223, Spain